Review



incucyte zoom  (Sartorius AG)


Bioz Verified Symbol Sartorius AG is a verified supplier
Bioz Manufacturer Symbol Sartorius AG manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    Sartorius AG incucyte zoom
    Incucyte Zoom, supplied by Sartorius AG, used in various techniques. Bioz Stars score: 99/100, based on 16193 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ag/Live+Cell+Analysis+Instruments/pm41963733-271-9-11
    Average 99 stars, based on 16193 article reviews
    incucyte zoom - by Bioz Stars, 2026-11
    99/100 stars

    Images

    Related Articles

    Cell Characterization:

    Article Title: Targeting YAP/TEAD signaling disturbs RNA Pol II activity and enhances immunotherapy response via activated cytosolic DNA sensing pathway in gastroesophageal cancer
    Article Snippet: Cells were cultured in RPMI1640 (Invitrogen) or DMEM (Invitrogen) and supplemented with 10% fetal bovine serum (FBS) (Invitrogen), 100 U/ml penicillin, and 100 mg/ml streptomycin (Invitrogen), and maintained at 37°C in a humidified incubator of 5% CO2. .. Live-Cell proliferation was measured using the IncuCyte cell count proliferation assay (Sartorius). ..

    Proliferation Assay:

    Article Title: Targeting YAP/TEAD signaling disturbs RNA Pol II activity and enhances immunotherapy response via activated cytosolic DNA sensing pathway in gastroesophageal cancer
    Article Snippet: Cells were cultured in RPMI1640 (Invitrogen) or DMEM (Invitrogen) and supplemented with 10% fetal bovine serum (FBS) (Invitrogen), 100 U/ml penicillin, and 100 mg/ml streptomycin (Invitrogen), and maintained at 37°C in a humidified incubator of 5% CO2. .. Live-Cell proliferation was measured using the IncuCyte cell count proliferation assay (Sartorius). ..

    Software:

    Article Title: Species-specific inflammatory responses of chondrocytes: Toward evidence-based model selection in OA research
    Article Snippet: .. IncuCyte software analysis , Sartorius , RRID:SCR_003935; https://www.sartorius.com/en/product. ..

    Article Title: Targeting CD28 on T lineage malignancies with chimeric antigen receptor T cells.
    Article Snippet: .. Quantification of cellular abundance was performed as recommended by measuring GFP integrated intensity in at least technical triplicates (Sartorius, Incucyte Software Version 2023A-2025B). ..

    Article Title: Astrocytes regulate axonal mitochondrial transport deficits in C9ORF72 amyotrophic lateral sclerosis motor neurons.
    Article Snippet: .. Software and code Policy information about availability of computer code Data collection Zeiss Zen software (Carl Zeiss), Seahorse Wave Desktop Software v2.6 (Agilent Technologies), Harmony software v4.9 (PerkinElmer), IncuCyte software (Sartorius), and ImageJ/Fiji v2.14. .. Data analysis GraphPad Prism v10, R v4.3.2 (including lme4, car, emmeans and DESeq2 packages), and ImageJ/Fiji v2.14 For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers.

    Analysis:

    Article Title: Species-specific inflammatory responses of chondrocytes: Toward evidence-based model selection in OA research
    Article Snippet: .. IncuCyte software analysis , Sartorius , RRID:SCR_003935; https://www.sartorius.com/en/product. ..

    Article Title: Differential effects of propranolol enantiomers on haemangioma-derived endothelial spheroids
    Article Snippet: The spheroids were embedded in Cultrex Reduced Growth Factor Basement Membrane Extract (R&D Systems, NE Minneapolis, MN, USA) at a concentration of 4–5 mg/mL, following removal of growth medium and incubated at 37 °C to allow polymerisation. .. Culture media was added on top and whole spheroid area and the sprouting area was monitored over 3 days with the Incucyte Live-Cell Analysis (Sartorius, Essen Bio, Ann Arbor, MI, USA) with scans performed every 24 h using a 4 × objective. ..

    Article Title: Cold-Atmospheric-Plasma-Treated MSCs Retain Stem Cell Phenotype and Trilineage Differentiation Potential
    Article Snippet: .. Changes in hTERT-MSC fibroblast-like morphology were investigated following each treatment for the duration of the incubation (24, 48, 72 h) using the Incucyte Live-Cell https://doi.org/10.3390/plasma9040043 Analysis Instrument (Sartorius, Göttingen, Germany) in phase-contrast mode with the S3/SX 1 G/R Optical Module. .. To determine the MSC phenotype of hTERT-MSCs, the expression of positive markers CD105, CD90 and CD73 and the negative marker HLA/DR was analysed by flow cytometry using an MSC Phenotyping Cocktail Kit, anti-human, REAfinity (Miltenyi Biotec, Bisley, UK).

    Staining:

    Article Title: Gasdermin D-mediated delivery of caspase inhibitors to suppress pyroptosis.
    Article Snippet: Caspase-1, -4, -5 and -11 activate gasdermin D (GSDMD) pores, causing pyroptotic cell death and the release of the interleukins IL-1β and IL-18 (ref. 1).. Blocking this pathway holds therapeutic promise for the treatment of inflammatory disorders, but cellpermeable caspase inhibitors have not proved successful in clinical trials.. Here we describe covalent caspase inhibitors that selectively block pyroptosis and IL-1β secretion despite being excluded from healthy cells.

    Morphology:

    Article Title: Cold-Atmospheric-Plasma-Treated MSCs Retain Stem Cell Phenotype and Trilineage Differentiation Potential
    Article Snippet: .. Changes in hTERT-MSC fibroblast-like morphology were investigated following each treatment for the duration of the incubation (24, 48, 72 h) using the Incucyte Live-Cell https://doi.org/10.3390/plasma9040043 Analysis Instrument (Sartorius, Göttingen, Germany) in phase-contrast mode with the S3/SX 1 G/R Optical Module. .. To determine the MSC phenotype of hTERT-MSCs, the expression of positive markers CD105, CD90 and CD73 and the negative marker HLA/DR was analysed by flow cytometry using an MSC Phenotyping Cocktail Kit, anti-human, REAfinity (Miltenyi Biotec, Bisley, UK).

    Incubation:

    Article Title: Cold-Atmospheric-Plasma-Treated MSCs Retain Stem Cell Phenotype and Trilineage Differentiation Potential
    Article Snippet: .. Changes in hTERT-MSC fibroblast-like morphology were investigated following each treatment for the duration of the incubation (24, 48, 72 h) using the Incucyte Live-Cell https://doi.org/10.3390/plasma9040043 Analysis Instrument (Sartorius, Göttingen, Germany) in phase-contrast mode with the S3/SX 1 G/R Optical Module. .. To determine the MSC phenotype of hTERT-MSCs, the expression of positive markers CD105, CD90 and CD73 and the negative marker HLA/DR was analysed by flow cytometry using an MSC Phenotyping Cocktail Kit, anti-human, REAfinity (Miltenyi Biotec, Bisley, UK).

    Phase Contrast:

    Article Title: Cold-Atmospheric-Plasma-Treated MSCs Retain Stem Cell Phenotype and Trilineage Differentiation Potential
    Article Snippet: .. Changes in hTERT-MSC fibroblast-like morphology were investigated following each treatment for the duration of the incubation (24, 48, 72 h) using the Incucyte Live-Cell https://doi.org/10.3390/plasma9040043 Analysis Instrument (Sartorius, Göttingen, Germany) in phase-contrast mode with the S3/SX 1 G/R Optical Module. .. To determine the MSC phenotype of hTERT-MSCs, the expression of positive markers CD105, CD90 and CD73 and the negative marker HLA/DR was analysed by flow cytometry using an MSC Phenotyping Cocktail Kit, anti-human, REAfinity (Miltenyi Biotec, Bisley, UK).



    Similar Products

    96
    Fujirebio Inc innotest htau ag
    Innotest Htau Ag, supplied by Fujirebio Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ag/INNOTEST+hTAU+Ag/custom%4081572%4042956044
    Average 96 stars, based on 1 article reviews
    innotest htau ag - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    99
    Envigo pathogen free c57bl 6j olahsd immune competent female mice
    Pathogen Free C57bl 6j Olahsd Immune Competent Female Mice, supplied by Envigo, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ag/C57BL%2F6+aged+inbred+mice/10__22203_slash_ecm__v033a11-101-1-8
    Average 99 stars, based on 1 article reviews
    pathogen free c57bl 6j olahsd immune competent female mice - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    90
    brain products gmbh ag-agcl scalp electrodes
    Ag Agcl Scalp Electrodes, supplied by brain products gmbh, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ag/scalp+electrodes/nct05668923-4-6-25
    Average 90 stars, based on 1 article reviews
    ag-agcl scalp electrodes - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    86
    Charles River Laboratories age
    Age, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ag/age+matched/pmc12819348-52-12-17
    Average 86 stars, based on 1 article reviews
    age - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    95
    Fujirebio Inc lumipulse g sars cov 2 ag assay
    Quantification of N-antigenemia and association with multiple immunological and virological parameters. (A) Comparison of plasma N-antigenemia concentrations among patients with respiratory infections <t>caused</t> by <t>SARS-CoV-2</t> presenting mild symptoms (n = 100, orange) or severe disease (n = 66, blue, discovery cohort), patients with severe influenza infection (n = 21, white), and non-infected HCs (n = 30, grey). Horizontal continuous black lines represent the median value. The dotted black line represents the positive cut-off and the dotted grey line the LLOQ. Values below the LLOQ but above the LLOD were retained without modification; values below the LLOD were imputed using the formula LLOQ/√2. (B) Graphical representation of the multiparametric analysis comparing N-antigenemia levels in patients with severe COVID-19 with 45 parameters. (C) Correlations in patients with severe COVID-19 between N-antigenemia level and viral load, endothelium and pulmonary damage markers, IgG anti-RBD, mRNA expression level of 26-immune pathways related genes (FilmArray®IPP panel, BioFire Diagnostics, Salt Lake City, UT, USA), circulating pro-inflammatory and immune-related protein concentrations. Significant positive correlations are in purple and negative correlations in orange; non-significant correlations i.e. below the cut-off threshold of 0.05 (discontinuous red line) are in black. Sample size varies for each parameter due to the exclusion of missing values (from n = 37 to n = 65); the exact sample size for each correlation is given in . (D) Correlations of N-antigenemia levels (x-axis) with circulating IFN-α 2 concentration (n = 65); OAS2 (n = 60) and CXCL10 (n = 60) expression; and IgG anti-RBD concentration (n = 53; y-axis). Each dot represents a serum sample from a patient with severe COVID-19, the solid black line represents the linear regression, and the grey area indicates the 95% CI. Comparisons are performed using non-parametric Kruskal–Wallis test with Dunn's post-hoc correction for multiple comparison and correlation using Spearman's rank correlation coefficient (ρ) with Benjamini-Hochberg post-hoc correction for multiple-comparison. ∗∗∗∗ p < 0 . 0001 . All analyses were performed using independent biological replicates. Abbreviations: BAU, binding antibody unit; CI, confidence interval; HCs, Healthy controls; ICU, intensive care unit; IFN, interferon; IgG, immunoglobulin G; LLOD, lower limit of detection; LLOQ, lower limit of quantification; RBD, receptor binding domain.
    Lumipulse G Sars Cov 2 Ag Assay, supplied by Fujirebio Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ag/Lumipulse+G+SARS-CoV-2+Ag/pmc13682480-82-9-9
    Average 95 stars, based on 1 article reviews
    lumipulse g sars cov 2 ag assay - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    ages  (Bioss)
    95
    Bioss ages
    Quantification of N-antigenemia and association with multiple immunological and virological parameters. (A) Comparison of plasma N-antigenemia concentrations among patients with respiratory infections <t>caused</t> by <t>SARS-CoV-2</t> presenting mild symptoms (n = 100, orange) or severe disease (n = 66, blue, discovery cohort), patients with severe influenza infection (n = 21, white), and non-infected HCs (n = 30, grey). Horizontal continuous black lines represent the median value. The dotted black line represents the positive cut-off and the dotted grey line the LLOQ. Values below the LLOQ but above the LLOD were retained without modification; values below the LLOD were imputed using the formula LLOQ/√2. (B) Graphical representation of the multiparametric analysis comparing N-antigenemia levels in patients with severe COVID-19 with 45 parameters. (C) Correlations in patients with severe COVID-19 between N-antigenemia level and viral load, endothelium and pulmonary damage markers, IgG anti-RBD, mRNA expression level of 26-immune pathways related genes (FilmArray®IPP panel, BioFire Diagnostics, Salt Lake City, UT, USA), circulating pro-inflammatory and immune-related protein concentrations. Significant positive correlations are in purple and negative correlations in orange; non-significant correlations i.e. below the cut-off threshold of 0.05 (discontinuous red line) are in black. Sample size varies for each parameter due to the exclusion of missing values (from n = 37 to n = 65); the exact sample size for each correlation is given in . (D) Correlations of N-antigenemia levels (x-axis) with circulating IFN-α 2 concentration (n = 65); OAS2 (n = 60) and CXCL10 (n = 60) expression; and IgG anti-RBD concentration (n = 53; y-axis). Each dot represents a serum sample from a patient with severe COVID-19, the solid black line represents the linear regression, and the grey area indicates the 95% CI. Comparisons are performed using non-parametric Kruskal–Wallis test with Dunn's post-hoc correction for multiple comparison and correlation using Spearman's rank correlation coefficient (ρ) with Benjamini-Hochberg post-hoc correction for multiple-comparison. ∗∗∗∗ p < 0 . 0001 . All analyses were performed using independent biological replicates. Abbreviations: BAU, binding antibody unit; CI, confidence interval; HCs, Healthy controls; ICU, intensive care unit; IFN, interferon; IgG, immunoglobulin G; LLOD, lower limit of detection; LLOQ, lower limit of quantification; RBD, receptor binding domain.
    Ages, supplied by Bioss, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ag/AGEs/pmc13691523-66-0-5
    Average 95 stars, based on 1 article reviews
    ages - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    99
    ATCC ags cells
    Quantification of N-antigenemia and association with multiple immunological and virological parameters. (A) Comparison of plasma N-antigenemia concentrations among patients with respiratory infections <t>caused</t> by <t>SARS-CoV-2</t> presenting mild symptoms (n = 100, orange) or severe disease (n = 66, blue, discovery cohort), patients with severe influenza infection (n = 21, white), and non-infected HCs (n = 30, grey). Horizontal continuous black lines represent the median value. The dotted black line represents the positive cut-off and the dotted grey line the LLOQ. Values below the LLOQ but above the LLOD were retained without modification; values below the LLOD were imputed using the formula LLOQ/√2. (B) Graphical representation of the multiparametric analysis comparing N-antigenemia levels in patients with severe COVID-19 with 45 parameters. (C) Correlations in patients with severe COVID-19 between N-antigenemia level and viral load, endothelium and pulmonary damage markers, IgG anti-RBD, mRNA expression level of 26-immune pathways related genes (FilmArray®IPP panel, BioFire Diagnostics, Salt Lake City, UT, USA), circulating pro-inflammatory and immune-related protein concentrations. Significant positive correlations are in purple and negative correlations in orange; non-significant correlations i.e. below the cut-off threshold of 0.05 (discontinuous red line) are in black. Sample size varies for each parameter due to the exclusion of missing values (from n = 37 to n = 65); the exact sample size for each correlation is given in . (D) Correlations of N-antigenemia levels (x-axis) with circulating IFN-α 2 concentration (n = 65); OAS2 (n = 60) and CXCL10 (n = 60) expression; and IgG anti-RBD concentration (n = 53; y-axis). Each dot represents a serum sample from a patient with severe COVID-19, the solid black line represents the linear regression, and the grey area indicates the 95% CI. Comparisons are performed using non-parametric Kruskal–Wallis test with Dunn's post-hoc correction for multiple comparison and correlation using Spearman's rank correlation coefficient (ρ) with Benjamini-Hochberg post-hoc correction for multiple-comparison. ∗∗∗∗ p < 0 . 0001 . All analyses were performed using independent biological replicates. Abbreviations: BAU, binding antibody unit; CI, confidence interval; HCs, Healthy controls; ICU, intensive care unit; IFN, interferon; IgG, immunoglobulin G; LLOD, lower limit of detection; LLOQ, lower limit of quantification; RBD, receptor binding domain.
    Ags Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ag/AGS/pm42905520-268-0-13
    Average 99 stars, based on 1 article reviews
    ags cells - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    99
    ATCC human gastric adenocarcinoma cell lines ags
    Quantification of N-antigenemia and association with multiple immunological and virological parameters. (A) Comparison of plasma N-antigenemia concentrations among patients with respiratory infections <t>caused</t> by <t>SARS-CoV-2</t> presenting mild symptoms (n = 100, orange) or severe disease (n = 66, blue, discovery cohort), patients with severe influenza infection (n = 21, white), and non-infected HCs (n = 30, grey). Horizontal continuous black lines represent the median value. The dotted black line represents the positive cut-off and the dotted grey line the LLOQ. Values below the LLOQ but above the LLOD were retained without modification; values below the LLOD were imputed using the formula LLOQ/√2. (B) Graphical representation of the multiparametric analysis comparing N-antigenemia levels in patients with severe COVID-19 with 45 parameters. (C) Correlations in patients with severe COVID-19 between N-antigenemia level and viral load, endothelium and pulmonary damage markers, IgG anti-RBD, mRNA expression level of 26-immune pathways related genes (FilmArray®IPP panel, BioFire Diagnostics, Salt Lake City, UT, USA), circulating pro-inflammatory and immune-related protein concentrations. Significant positive correlations are in purple and negative correlations in orange; non-significant correlations i.e. below the cut-off threshold of 0.05 (discontinuous red line) are in black. Sample size varies for each parameter due to the exclusion of missing values (from n = 37 to n = 65); the exact sample size for each correlation is given in . (D) Correlations of N-antigenemia levels (x-axis) with circulating IFN-α 2 concentration (n = 65); OAS2 (n = 60) and CXCL10 (n = 60) expression; and IgG anti-RBD concentration (n = 53; y-axis). Each dot represents a serum sample from a patient with severe COVID-19, the solid black line represents the linear regression, and the grey area indicates the 95% CI. Comparisons are performed using non-parametric Kruskal–Wallis test with Dunn's post-hoc correction for multiple comparison and correlation using Spearman's rank correlation coefficient (ρ) with Benjamini-Hochberg post-hoc correction for multiple-comparison. ∗∗∗∗ p < 0 . 0001 . All analyses were performed using independent biological replicates. Abbreviations: BAU, binding antibody unit; CI, confidence interval; HCs, Healthy controls; ICU, intensive care unit; IFN, interferon; IgG, immunoglobulin G; LLOD, lower limit of detection; LLOQ, lower limit of quantification; RBD, receptor binding domain.
    Human Gastric Adenocarcinoma Cell Lines Ags, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ag/AGS/10__3390_slash_ijms27209228-133-1-9
    Average 99 stars, based on 1 article reviews
    human gastric adenocarcinoma cell lines ags - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    Image Search Results


    Quantification of N-antigenemia and association with multiple immunological and virological parameters. (A) Comparison of plasma N-antigenemia concentrations among patients with respiratory infections caused by SARS-CoV-2 presenting mild symptoms (n = 100, orange) or severe disease (n = 66, blue, discovery cohort), patients with severe influenza infection (n = 21, white), and non-infected HCs (n = 30, grey). Horizontal continuous black lines represent the median value. The dotted black line represents the positive cut-off and the dotted grey line the LLOQ. Values below the LLOQ but above the LLOD were retained without modification; values below the LLOD were imputed using the formula LLOQ/√2. (B) Graphical representation of the multiparametric analysis comparing N-antigenemia levels in patients with severe COVID-19 with 45 parameters. (C) Correlations in patients with severe COVID-19 between N-antigenemia level and viral load, endothelium and pulmonary damage markers, IgG anti-RBD, mRNA expression level of 26-immune pathways related genes (FilmArray®IPP panel, BioFire Diagnostics, Salt Lake City, UT, USA), circulating pro-inflammatory and immune-related protein concentrations. Significant positive correlations are in purple and negative correlations in orange; non-significant correlations i.e. below the cut-off threshold of 0.05 (discontinuous red line) are in black. Sample size varies for each parameter due to the exclusion of missing values (from n = 37 to n = 65); the exact sample size for each correlation is given in . (D) Correlations of N-antigenemia levels (x-axis) with circulating IFN-α 2 concentration (n = 65); OAS2 (n = 60) and CXCL10 (n = 60) expression; and IgG anti-RBD concentration (n = 53; y-axis). Each dot represents a serum sample from a patient with severe COVID-19, the solid black line represents the linear regression, and the grey area indicates the 95% CI. Comparisons are performed using non-parametric Kruskal–Wallis test with Dunn's post-hoc correction for multiple comparison and correlation using Spearman's rank correlation coefficient (ρ) with Benjamini-Hochberg post-hoc correction for multiple-comparison. ∗∗∗∗ p < 0 . 0001 . All analyses were performed using independent biological replicates. Abbreviations: BAU, binding antibody unit; CI, confidence interval; HCs, Healthy controls; ICU, intensive care unit; IFN, interferon; IgG, immunoglobulin G; LLOD, lower limit of detection; LLOQ, lower limit of quantification; RBD, receptor binding domain.

    Journal: eBioMedicine

    Article Title: Sustained type I interferon activity and N-antigenemia form a vicious cycle during severe COVID-19

    doi: 10.1016/j.ebiom.2026.106508

    Figure Lengend Snippet: Quantification of N-antigenemia and association with multiple immunological and virological parameters. (A) Comparison of plasma N-antigenemia concentrations among patients with respiratory infections caused by SARS-CoV-2 presenting mild symptoms (n = 100, orange) or severe disease (n = 66, blue, discovery cohort), patients with severe influenza infection (n = 21, white), and non-infected HCs (n = 30, grey). Horizontal continuous black lines represent the median value. The dotted black line represents the positive cut-off and the dotted grey line the LLOQ. Values below the LLOQ but above the LLOD were retained without modification; values below the LLOD were imputed using the formula LLOQ/√2. (B) Graphical representation of the multiparametric analysis comparing N-antigenemia levels in patients with severe COVID-19 with 45 parameters. (C) Correlations in patients with severe COVID-19 between N-antigenemia level and viral load, endothelium and pulmonary damage markers, IgG anti-RBD, mRNA expression level of 26-immune pathways related genes (FilmArray®IPP panel, BioFire Diagnostics, Salt Lake City, UT, USA), circulating pro-inflammatory and immune-related protein concentrations. Significant positive correlations are in purple and negative correlations in orange; non-significant correlations i.e. below the cut-off threshold of 0.05 (discontinuous red line) are in black. Sample size varies for each parameter due to the exclusion of missing values (from n = 37 to n = 65); the exact sample size for each correlation is given in . (D) Correlations of N-antigenemia levels (x-axis) with circulating IFN-α 2 concentration (n = 65); OAS2 (n = 60) and CXCL10 (n = 60) expression; and IgG anti-RBD concentration (n = 53; y-axis). Each dot represents a serum sample from a patient with severe COVID-19, the solid black line represents the linear regression, and the grey area indicates the 95% CI. Comparisons are performed using non-parametric Kruskal–Wallis test with Dunn's post-hoc correction for multiple comparison and correlation using Spearman's rank correlation coefficient (ρ) with Benjamini-Hochberg post-hoc correction for multiple-comparison. ∗∗∗∗ p < 0 . 0001 . All analyses were performed using independent biological replicates. Abbreviations: BAU, binding antibody unit; CI, confidence interval; HCs, Healthy controls; ICU, intensive care unit; IFN, interferon; IgG, immunoglobulin G; LLOD, lower limit of detection; LLOQ, lower limit of quantification; RBD, receptor binding domain.

    Article Snippet: SARS-CoV-2 N-antigenemia was quantified from serum samples using the Lumipulse G SARS-CoV-2 Ag assay (Fujirebio Holdings Inc., Tokyo, Japan, 260,340) performed on the Lumipulse G600II automated immunoassay analyser (Fujirebio; RRID: SCR_018018 , ).

    Techniques: Comparison, Clinical Proteomics, Infection, Modification, Analysis, Expressing, Concentration Assay, Blood/Plasma/Serum Samples, Binding Assay

    SARS-CoV-2 N-antigenemia and IFN-α 2 secretion dynamics over the course of the disease in patients with severe COVID-19. Temporal kinetics of SARS-CoV-2 N- antigenemia (385 longitudinal samples from 134 patients) (A) and circulating IFN-α 2 concentration (395 longitudinal samples from 134 patients) (B); expressed as log 2 pg/mL and fg/mL, respectively, and the sigmoidal relationship between both parameters among positive N-antigenemia and IFN-α 2 concentration levels (239 longitudinal samples from 124 patients) (C), according to the DPSO (days) in patients with severe COVID-19 included in the confirmation cohort. Each circle denotes an individual serum measurement; paired values from the same patient are connected by thin lines. (D) Pseudo-kinetic profiles derived from a k-means algorithm applied to patients with longitudinal samples available between DPSO 0 to 40 only (366 longitudinal samples from 116 patients) are depicted with three independently fitted models focussing on DPSO 0 to 30 to mitigate low counts per cluster at later time points. The continuous curve depicts the nonlinear dynamics of the parameters over the course of the disease, or their sigmoidal relationship, while the shaded area represents the 95% CI, reflecting both fixed-effect estimation uncertainty and variability due to patient-level random effects. All these analyses were performed using generalised additive models including a random intercept to account for inter-individual variability. All analyses were performed using independent biological replicates. Abbreviations: CI, confidence interval; DPSO, days post-symptom onset; IFN, interferon.

    Journal: eBioMedicine

    Article Title: Sustained type I interferon activity and N-antigenemia form a vicious cycle during severe COVID-19

    doi: 10.1016/j.ebiom.2026.106508

    Figure Lengend Snippet: SARS-CoV-2 N-antigenemia and IFN-α 2 secretion dynamics over the course of the disease in patients with severe COVID-19. Temporal kinetics of SARS-CoV-2 N- antigenemia (385 longitudinal samples from 134 patients) (A) and circulating IFN-α 2 concentration (395 longitudinal samples from 134 patients) (B); expressed as log 2 pg/mL and fg/mL, respectively, and the sigmoidal relationship between both parameters among positive N-antigenemia and IFN-α 2 concentration levels (239 longitudinal samples from 124 patients) (C), according to the DPSO (days) in patients with severe COVID-19 included in the confirmation cohort. Each circle denotes an individual serum measurement; paired values from the same patient are connected by thin lines. (D) Pseudo-kinetic profiles derived from a k-means algorithm applied to patients with longitudinal samples available between DPSO 0 to 40 only (366 longitudinal samples from 116 patients) are depicted with three independently fitted models focussing on DPSO 0 to 30 to mitigate low counts per cluster at later time points. The continuous curve depicts the nonlinear dynamics of the parameters over the course of the disease, or their sigmoidal relationship, while the shaded area represents the 95% CI, reflecting both fixed-effect estimation uncertainty and variability due to patient-level random effects. All these analyses were performed using generalised additive models including a random intercept to account for inter-individual variability. All analyses were performed using independent biological replicates. Abbreviations: CI, confidence interval; DPSO, days post-symptom onset; IFN, interferon.

    Article Snippet: SARS-CoV-2 N-antigenemia was quantified from serum samples using the Lumipulse G SARS-CoV-2 Ag assay (Fujirebio Holdings Inc., Tokyo, Japan, 260,340) performed on the Lumipulse G600II automated immunoassay analyser (Fujirebio; RRID: SCR_018018 , ).

    Techniques: Concentration Assay, Derivative Assay

    Distinct trajectories of SARS-CoV-2 N-antigenemia and association with impaired or sustained IFN-I response. (A) Longitudinal plasma SARS-CoV-2 N-antigenemia according to DPSO, using 60 serial blood samples of the 22 patients with severe COVID-19 from the validation cohort. Clusters obtained in the confirmation cohort dataset were transferred to the validation cohort using a random forest model, enabling the identification of patients with sustained high N-antigenemia (red; 4/22) and low or decreasing N-antigenemia over the course of the disease (grey; 18/22). Group trajectories are shown with linear mixed-effects regression lines, and 95% CI. The dotted line indicates the positivity threshold. (B) Heatmap of virological and IFN-related parameters over time in the two N-antigenemia clusters. One individual, with two unique samples at day 18 and 21 was excluded (60 longitudinal samples from 21 patients). Rows represent the median of plasma N-antigenemia, plasma IFN-α2 concentration, nasal viral load, blood IFN-I score, and nasal IFN-I score. Columns correspond to DPSO intervals (days 1–3, 4–6, 7–9, and ≥10). Values are scaled per row using min–max normalisation and displayed with increasing intensity of colour from low to high. Line plots on the right illustrate temporal trends (median value) for each parameter in both clusters. All analyses were performed using independent biological replicates. Abbreviations: AANs, neutralising autoantibodies; DPSO, days post-symptom onset; IFN, interferon; ISG, interferon-stimulated genes.

    Journal: eBioMedicine

    Article Title: Sustained type I interferon activity and N-antigenemia form a vicious cycle during severe COVID-19

    doi: 10.1016/j.ebiom.2026.106508

    Figure Lengend Snippet: Distinct trajectories of SARS-CoV-2 N-antigenemia and association with impaired or sustained IFN-I response. (A) Longitudinal plasma SARS-CoV-2 N-antigenemia according to DPSO, using 60 serial blood samples of the 22 patients with severe COVID-19 from the validation cohort. Clusters obtained in the confirmation cohort dataset were transferred to the validation cohort using a random forest model, enabling the identification of patients with sustained high N-antigenemia (red; 4/22) and low or decreasing N-antigenemia over the course of the disease (grey; 18/22). Group trajectories are shown with linear mixed-effects regression lines, and 95% CI. The dotted line indicates the positivity threshold. (B) Heatmap of virological and IFN-related parameters over time in the two N-antigenemia clusters. One individual, with two unique samples at day 18 and 21 was excluded (60 longitudinal samples from 21 patients). Rows represent the median of plasma N-antigenemia, plasma IFN-α2 concentration, nasal viral load, blood IFN-I score, and nasal IFN-I score. Columns correspond to DPSO intervals (days 1–3, 4–6, 7–9, and ≥10). Values are scaled per row using min–max normalisation and displayed with increasing intensity of colour from low to high. Line plots on the right illustrate temporal trends (median value) for each parameter in both clusters. All analyses were performed using independent biological replicates. Abbreviations: AANs, neutralising autoantibodies; DPSO, days post-symptom onset; IFN, interferon; ISG, interferon-stimulated genes.

    Article Snippet: SARS-CoV-2 N-antigenemia was quantified from serum samples using the Lumipulse G SARS-CoV-2 Ag assay (Fujirebio Holdings Inc., Tokyo, Japan, 260,340) performed on the Lumipulse G600II automated immunoassay analyser (Fujirebio; RRID: SCR_018018 , ).

    Techniques: Clinical Proteomics, Blood/Plasma/Serum Samples, Biomarker Discovery, Concentration Assay, Autoantibodies

    Proportion and impact of neutralising anti–IFN-α2 autoantibodies (AAN--IFN-α 2 ) on N-antigenemia and IFN-α 2 levels. (A) Comparison of IFN-α 2 levels according to the presence (n = 10) or absence (n = 210) of AAN-IFN-α 2 , assessed in 220 samples collected at admission of patients with severe COVID-19 across the discovery, validation, and confirmation cohorts, plus five additional patients with severe COVID-19. Comparisons were performed using the non-parametric Wilcoxon test. ∗∗ p < 0.01 and ∗∗∗∗ p < 0.001 . (B) Proportion of patients with severe COVID-19 with detectable N-antigenemia according to the presence of AAN-IFN-α 2 within the same patients. Horizontal continuous black lines represent the median value. Stacked bars show the proportions of N-antigenemia–positive and –negative patients. Groups are compared using Fisher's exact test ( p . value shown). (C) Medical history and clinical course of patient #2, adapted from Bussy et al. a patient suffering from severe COVID-19 with a severe hypoxaemic state and positive for AAN-IFN-β. SARS-CoV-2 viral load and the PaO2/FiO2 ratio were obtained from the NPS sample, whereas N-antigenemia and IFN-α 2 concentrations were measured in blood samples. Discontinuous line indicates positive cut-off or LLOQ. IFN-α2 are expressed as fg/mL and N-antigenemia as pg/mL. All analyses were performed using independent biological replicates. Abbreviations: AAN, neutralising autoantibodies; ATB, antibiotic; FiO2, fraction of inspiratory oxygen; ICU, intensive care unit; IFN, interferon; LLOD, lower limit of detection; LLOQ, lower limit of quantification; NS, not significant; NPS, nasopharyngeal swab; PaO2, partial pressure of oxygen.

    Journal: eBioMedicine

    Article Title: Sustained type I interferon activity and N-antigenemia form a vicious cycle during severe COVID-19

    doi: 10.1016/j.ebiom.2026.106508

    Figure Lengend Snippet: Proportion and impact of neutralising anti–IFN-α2 autoantibodies (AAN--IFN-α 2 ) on N-antigenemia and IFN-α 2 levels. (A) Comparison of IFN-α 2 levels according to the presence (n = 10) or absence (n = 210) of AAN-IFN-α 2 , assessed in 220 samples collected at admission of patients with severe COVID-19 across the discovery, validation, and confirmation cohorts, plus five additional patients with severe COVID-19. Comparisons were performed using the non-parametric Wilcoxon test. ∗∗ p < 0.01 and ∗∗∗∗ p < 0.001 . (B) Proportion of patients with severe COVID-19 with detectable N-antigenemia according to the presence of AAN-IFN-α 2 within the same patients. Horizontal continuous black lines represent the median value. Stacked bars show the proportions of N-antigenemia–positive and –negative patients. Groups are compared using Fisher's exact test ( p . value shown). (C) Medical history and clinical course of patient #2, adapted from Bussy et al. a patient suffering from severe COVID-19 with a severe hypoxaemic state and positive for AAN-IFN-β. SARS-CoV-2 viral load and the PaO2/FiO2 ratio were obtained from the NPS sample, whereas N-antigenemia and IFN-α 2 concentrations were measured in blood samples. Discontinuous line indicates positive cut-off or LLOQ. IFN-α2 are expressed as fg/mL and N-antigenemia as pg/mL. All analyses were performed using independent biological replicates. Abbreviations: AAN, neutralising autoantibodies; ATB, antibiotic; FiO2, fraction of inspiratory oxygen; ICU, intensive care unit; IFN, interferon; LLOD, lower limit of detection; LLOQ, lower limit of quantification; NS, not significant; NPS, nasopharyngeal swab; PaO2, partial pressure of oxygen.

    Article Snippet: SARS-CoV-2 N-antigenemia was quantified from serum samples using the Lumipulse G SARS-CoV-2 Ag assay (Fujirebio Holdings Inc., Tokyo, Japan, 260,340) performed on the Lumipulse G600II automated immunoassay analyser (Fujirebio; RRID: SCR_018018 , ).

    Techniques: Autoantibodies, Comparison, Biomarker Discovery, Blood/Plasma/Serum Samples